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AbstrACt
background The interaction of the gut microbiota 
with the human host is implicated in the 
pathogenesis of inflammatory and immunological 
diseases including ulcerative colitis (UC). 
Faecal microbiota transplantation (FMT) as a 
method of restoring gut microbial diversity is of 
increasing interest as a therapeutic approach 
in the management of UC. The current literature 
lacks consensus about the dose of FMT, route of 
administration and duration of response.
Methods and analysis This single-blinded 
randomised trial will explore the feasibility of FMT 
in 30 treatment-naïve patients with histologically 
confirmed distal UC limited to the recto-sigmoid 
region (up to 40 cm from the anal verge). This study 
aims to estimate the magnitude of treatment response 
to FMT under controlled conditions. The intervention 
(FMT) will be administered by rectal retention enema. 
It will test the feasibility of randomising patients to: 
(i) single FMT dose, (ii) five daily FMT doses or (iii) 
control (no FMT dose). All groups will receive standard 
antibiotic gut decontamination and bowel preparation 
before FMT. Recruitment will take place over a 
24-month period with a 12-week patient follow-up. 
Trial objectives include evaluation of the magnitude of 
treatment response to FMT, investigation of the clinical 
value of metabolic phenotyping for predicting the 
clinical response to FMT and testing the recruitment 
rate of donors and patients for a study in FMT. This 
feasibility trial will enable an estimate of number 
of patients needed, help determine optimal study 
conditions and inform the choice of endpoints for a 
future definitive phase III study.
Ethics and dissemination The trial is approved by 
the regional ethics committee and is sponsored by 
Abertawe Bro Morgannwg University's Health Board. 
Written informed consent from all patients will be 
obtained. Serious adverse events will be reported to 
the sponsor. Trial results will be disseminated via peer 
review publication and shared with trial participants.
trial registration number ISRCTN 58082603; Pre-
results.
IntroduCtIon
Ulcerative colitis (UC) is a chronic relaps-
ing-remitting mucosal inflammatory bowel 
disease (IBD). Clinical features include 
rectal bleeding, diarrhoea, faecal urgency, 
fatigue and weight loss. The aetiology of 
UC is believed to be multifactorial involving 
immune dysregulation, mucosal disrup-
tion and genetic predisposition, though the 
precise cause is poorly understood.1 
There is no curative treatment at present; 
thus the aim of current management is 
induction and maintenance of remission with 
immunosuppressive agents. Failure of medical 
therapy or refractory disease may require 
major resectional surgery with temporary or 
permanent ostomy formation. UC is also a 
recognised risk factor for colorectal cancer 
requiring lifelong surveillance.2 However, it 
is uncertain how to predict which group of 
patients will respond to medical therapy.
The human gut microbiota consists of a 
diverse biological environment comprising 
bacteria, viruses and fungi within the gut 
strengths and limitations of this study
 ► This is one of the first trials to have a homogeneous 
study group of newly diagnosed and treatment naïve 
patients with ulcerative colitis (UC).
 ► The trial will not only show the efficacy of faecal 
microbiota transplantation (FMT) treatment by rectal 
administration, but also help to define the optimal 
number of doses of FMT for treatment of UC.
 ► Metabolomic analysis will demonstrate mechanism 
of action of FMT in treatment responders.
 ► Patient's reported quality of life measures will be 
reported.
 ► This study is limited by a short (12 weeks) follow-up 
period.
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lumen and lining mucosa. The biodiversity of the gut 
microbiota is a dynamic process and is known to be 
affected by age, diet and lifestyle.3 4 It has been referred 
as a hidden metabolic organ through its major role is as 
a driver of metabolic and immunological communica-
tions and the regulation of the immunological processes 
within the intestinal mucosa.5–7 Disruption of the gut 
microbiota, also called dysbiosis, has been suggested to 
be responsible for not only intestinal pathology such as 
Clostridium difficile infection, but also for systemic condi-
tions such as obesity, diabetes mellitus and IBD including 
UC.3 8 The role of gut microbiota with host–microbiome 
interactions are likely to be a key driver in the patho-
genesis of UC.9 10 Antibiotics, which alter the human 
gut microbiome, have been shown to contribute to UC 
activity,11 whereas probiotics have been implicated in UC 
remission.12 The gut microbiota of patients with UC lacks 
diversity13 14 and Bacteroidetes and Firmicutes are found in 
significantly less amounts in the microbiota of patients 
with UC.13 15 Furthermore, reduced amounts of bacterial 
producers of short-chain fatty acids (SCFA) (butyrate, 
propionate and acetate) are found in the microbiota of 
patients with UC.16 17 These SCFAs are products of starch 
fermentation from gut bacteria and are believed to have 
anti-inflammatory properties. Moreover, recent studies 
have shown that butyrate produced from Faecalibacterium 
prausnitzii not only has anti-inflammatory properties, 
but also provides the major nutrient for colonocytes,18 
and prevents intestinal mucosa atrophy and colono-
cyte autophagy.19 A number of studies demonstrate that 
the butyrate producer F. prausnitzii was less abundant 
in patients with UC.20–22 Moreover, recent studies have 
suggested that not only living bacteria may be responsible 
inflammatory process of UC, but also bacterial specific 
components and structures, antimicrobial compounds 
and metabolites produced by bacteria may contribute 
to the gut microenvironment and thus its inflammatory 
process.23 Understanding of a critical role of secondary 
metabolites has also been highlighted recently by Buffie 
et al recently as they have indicated that certain species 
may inhibit C. difficile with their secondary metabolites, 
including secondary bile acids by Clostridium scindens.24 25 
Although the role of fungi in the human microbiome 
has not yet been fully understood, recent studies suggest 
microfragments of chitin, which is a substance produced 
by fungi and insects, display a significant immunomod-
ulatory impact in the inflammatory process.26 27 This 
suggests that not only viable common gut anaerobic 
micro-organisms, but also products and particles from 
other micro-organisms may be responsible for dysregula-
tion of the immune response. Despite extensive studies, 
no single pathogen has been identified as responsible for 
the pathogenesis of UC. The current consensus is that the 
loss of certain bacterial strains with immunomodulatory 
as well as mucosal regulatory functions leads to gut dysbi-
osis, resulting in the pathogenesis of UC. Faecal micro-
biota transplantation (FMT) is an infusion of a faecal 
suspension from a healthy individual (donor) to restore 
the dysbiosis of affected individuals (recipient). Since the 
approval of FMT in the management of recurrent C. diffi-
cile infections in 2014 by the National Institute for Health 
and Care Excellence (NICE), FMT has been of increasing 
interest as a therapeutic approach in the management of 
UC. If we can successfully and durably alter the colonic 
microbiota,28 it may be possible to achieve complete 
remission of this chronic debilitating disease without the 
use of lifelong immunosuppression or the need for major 
gastrointestinal surgery. The ability to induce remission 
and establish the microbiological basis for this would 
change the treatment paradigm for UC. Recent years 
have seen several randomised clinical studies emerging to 
investigate FMT in the management of UC with encour-
aging results.14 29–31 Despite these studies, many unknown 
aspects remain in the clinical application of FMT in UC, 
such as the optimum dose, route of administration and 
frequency of treatments. Equally it is not known whether 
FMT is effective as a first line treatment in drug-naïve 
patients. To study the optimum parameters for delivering 
FMT in UC and estimating the clinical response, this 
randomised feasibility trial was designed.
The objectives of this feasibility study include evalua-
tion of the magnitude of treatment response to FMT, 
investigation of the functional metabolic changes asso-
ciated with FMT using a metabolic phenotyping meth-
odology and testing the recruitment rate of donors and 
patients. Furthermore, we aim to measure the duration of 
clinical response with microbiome identification through 
16S rRNA sequencing and metabolomic analysis. This 
will facilitate the design of a definitive multicentred study 
to confirm the efficacy of FMT as a first-line treatment 
option in UC.
Primary objectives
The primary objective of this phase II study is to estimate 
the magnitude of the treatment response to FMT in treat-
ment naïve patients with UC.
secondary objectives
 ► Determine the recruitment rate of donors and partic-
ipants for a study of FMT.
 ► Determine the optimal study conditions and choice 
of endpoints for phase III study to include dosage and 
frequency of FMT treatments.
 ► Establish how many participants would be required 
for phase III to demonstrate the efficacy of FMT in 
the treatment of UC.
MEthods
This is a single-blinded interventional randomised feasi-
bility study to estimate the magnitude of the treatment 
response to FMT in newly diagnosed patients with distal 
UC who are treatment naïve. Recruitment is proposed 
over a 2-year period with a 12-week post-treatment 
follow-up period. This feasibility trial will help determine 
the recruitment rate of donors and participants, define 
the optimal study conditions and choice of endpoints for 
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a phase III definitive study. It will also allow us to establish 
how many participants would be required at phase III to 
demonstrate the efficacy of FMT in the treatment of UC.
trial design
We aim to recruit 30 subjects with histologically confirmed 
UC, whose disease is confined to the recto-sigmoid area 
(defined here as within 40 cm from the anal verge) and 
who are treatment naïve. Participants will be randomly 
assigned to study groups through a web-based application 
hosted by University of Aberdeen.
Eligible patients will be randomised into one of three 
groups with an allocation ratio of 2:2:1 as shown in table 1. 
Groups 1 and 2 are the intervention arms and 12 subjects 
will be assigned to each group respectively. Group 3 is the 
control arm and six subjects will be randomised into this 
group.
Intervention arms: groups 1 and 2
Participants randomly allocated to group 1 will receive 
one single FMT treatment administered as a rectal reten-
tion enema. Participants in group 2 will receive a single 
FMT treatment on five consecutive days (total of five 
treatments) also administered by rectal retention enema.
Control arm: group 3
Participants randomly allocated to group 3 will receive the 
pre-FMT preparation with antibiotics and bowel prepara-
tion but will not receive active FMT treatment.
Endpoints
Paired primary endpoints
 ► Remission of UC (mucosal healing) at 12 weeks 
as assessed by blinded sigmoidoscopy. Assessment 
defined as Mayo score ≤2 with an endoscopic Mayo 
score of 0
 ► Proportion of successful engraftment of donor faecal 
microbiota at 12 weeks in each group as analysed by 
16S sequencing and longitudinal diversity index
Secondary endpoints
 ► Rate of recruitment of patients
 ► Disease specific scores after treatment using IBDex 
severity scoring index,32 Crohns and Ulcerative Colitis 
Questionnaire  (CUCQ)-32 severity scoring index33 
and Mayo scoring system34
 ► Histological grading of colitis severity after treatment
 ► Mucosal immunological response to treatment (tissue 
IL-10 and IL-21 by ELISA)
 ► Rate of development of adverse effects to FMT
Participant selection
Potential participants will be identified by their usual 
clinicians in clinics and endoscopy units within the Health 
Board. Each potential participant will be screened for 
eligibility once he or she is referred to the research team. 
All subjects must have a definitive histological diagnosis 
of UC before enrolment as made by a gastrointestinal 
pathologist with a special interest in colitis. The minimum 
required microscopic features include cryptitis, crypt 
abcesses, crypt distortion and mucin depletion in the 
absence of granulomata. Participants with any features 
not consistent with UC will be excluded. A minimum time 
period of 1 month from identification to screening will 
exclude participants with acute self-limiting colitis.
A written patient information sheet will be provided 
and participants will be offered a minimum of 24 hours 
to consider enrolment before providing written informed 
consent.
During the screening visit, the study will be fully 
explained, and consent will be obtained if the subject 
satisfies all inclusion and exclusion criteria (box 1).
Interventions and investigational products
All three study groups will complete a 10-day course of 
oral antibiotics (Metronidazole 400 mg, vancomycin 
500 mg, rifampicin 150 mg twice daily), which should be 
completed at least 48 hours before the first FMT treat-
ment. This will allow the poorly absorbed vancomycin 
to wash out of the gastrointestinal tract. Patients should 
therefore start the 10-day course of antibiotics 12 days 
before the first FMT is given. These antibiotics were 
chosen following the recently published guidelines on 
FMT in clinical practice35 towards whole gut decontam-
ination. Additionally, all participants will receive bowel 
preparation (polyethylene glycol, 2 L) on the day before 
transplantation to prepare the lumen for engraftment of 
the FMT treatment and to minimise interference from 
the existing gut microbiota.
Investigational product
The investigational product is donated faecal material 
from healthy volunteers who are unrelated and non-co-
habiting to the study participants. The FMT products 
are obtained either from Wessex stool bank or material 
that has been locally processed using the identical FMT 
preparation technique by a physician for the purposes of 
the research trial. The pellet is resuspended and frozen 
in 20% glycerol and stored for up to 8 weeks at −80°C 
until the day of treatment. Donors are screened for infec-
tions in accordance with current best practice35 (table 2). 
In the case of multiple treatments (group 2) all doses 
Table 1 Intervention arms (groups 1 and 2) and control arm 
(group 3)
Group 1 Group 2 Group 3
Bowel 
decontamination 
and preparation
Yes Yes Yes
FMT treatment 
dose
1 Five consecutive 
days (single 
treatment per day)
None
Number of 
participants
12 12 6
FMT, faecal microbiota transplantation.
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are obtained from the same donor to minimise varia-
tion. Faecal microbiota of the donated faecal samples is 
studied using 16S rRNA analysis. This will be used as a 
reference for the effect of FMT treatments, evaluation of 
magnitude of treatment response to FMT and durability 
of engraftment after FMT.
Administration of investigational product
All three study groups will complete a 10-day course of 
oral antibiotics (vancomycin 500 mg; metronidazole 
400 mg, rifampicin 150 mg—all taken twice daily) and 
bowel preparation (polyethylene glycol 2 L on the day 
before transplantation). The first FMT treatment dose 
will be commenced 48 hours after the final dose of anti-
biotics to preserve the activity of the FMT. Frozen FMT 
will be thawed over 4 hours at room temperature prior 
to infusion, which will subsequently be diluted to 250 mL 
with non-bacteriostatic normal saline prior to infusion. 
The subjects of groups 1 and 2, who receive FMT treat-
ment, will also be given loperamide 4 mg orally 30 min 
prior to administration to maximise the chance of enema 
retention. Each participant receives 50 mL of enema every 
15 min over 60 min. The subjects will be encouraged to 
retain the treatment samples as long as possible (ideally 
more than 1 hour).
study setting
Recruitment will take place from clinics and endoscopy 
units within the Abertawe Bro Morgannwg University 
Health Board, Swansea. FMT will be administered at the 
Joint Clinical Research Facility within Swansea University.
randomisation
Study participants will be randomised 2:2:1 by a web-based 
method hosted by the University of Aberdeen’s Health 
Services Research Unit. The simple randomisation 
process employed in this allocation was not stratified 
by any factors (eg, age, gender). We aim to update the 
box 1 Participant selection criteria
Inclusion criteria
 ► Newly diagnosed histologically confirmed ulcerative colitis (UC) with 
inflammation limited to the rectum or recto-sigmoid (within 40 cm of 
anal verge as measured by flexible sigmoidoscopy).
 ► Age 18 years and older.
 ► Able to give full informed written consent.
 ► Willing to return for sequential faecal microbiota transplantation 
dosing and endoscopic assessment.
 ► Not in receipt of conventional medical treatment for colitis such as 
steroids or 5-aminosalicylic acid, that is, treatment naïve.
Exclusion criteria
 ► Patients without a definitive diagnosis of UC (for example, diagnosis 
of Crohn’s disease or infectious colitis).
 ► Colitis extending beyond 40 cm from the anal verge.
 ► Diagnosis of acute severe colitis (defined as greater than six 
blood-stained stools per 24 hours with one of the following: pulse 
rate>90/ temperature>37.8° /haemoglobin < 105 g/L / erythrocyte 
sedimentation rate>30).
 ► Abdominal tenderness on examination.
 ► Already commenced standard medical therapy for UC.
 ► Contraindication to oral bowel preparation.
 ► Allergy to study antibiotics.
 ► Age less than 18.
 ► Patient is within a vulnerable group, defined as people who are un-
able to take care of him or herself, or unable to protect him or herself 
against significant harm or exploitation.
 ► Pregnant.
 ► Immunosuppressed for example, transplant patient.
 ► Known communicable disease or at least 2 weeks full recovery from 
infectious disease for example, chickenpox.
 ► Systemic autoimmunity, or atopic diseases.
 ► Previous prosthetic implant (for example, metallic heart valve, joint 
replacement, ventricular-peritoneal shunt, cardiac stent),
 ► Chronic pain syndromes (for example, fibromyalgia, chronic fatigue).
 ► Neurologic, neurodevelopmental or neurodegenerative disorders.
 ► Depression (requiring therapy).
 ► Obesity (body mass index>35).
 ► Malignancy.
 ► Use of antibiotics for any indication within the past 3 months.
 ► Foreign travel to areas of enteric disease prevalence within 3 months.
 ► High-risk sexual behaviour (examples: sexual contact with anyone 
with HIV/human T-lymphocyte virus/AIDS or hepatitis B/C carrier, 
men who have sex with men).
 ► Known exposure to HIV or hepatitis B/C.
 ► Current/previous use of injected drugs or intranasal cocaine.
 ► Tattooing, piercing, cosmetic botulinum toxin or permanent makeup 
within 120 days (as per Welsh blood transfusion guidelines).
 ► Recent blood transfusion, tissue/organ transplant or skin graft.
 ► Risk factors for variant Creutzfeldt-Jakob disease, for  example, 
blood transfusion or transplant after 1 January 1980.
Table 2 Infectious disease screening
Blood tests  ► Cytomegalovirus.
 ► Epstein-Barr virus.
 ► Hepatitis A virus.
 ► Hepatitis B virus.
 ► Hepatitis C virus.
 ► Hepatitis E virus.
 ► Syphilis.
 ► HIV-1 and HIV-2.
 ► Entamoeba histolytica.
 ► Human T-lymphotropic virus types I and II 
antibodies.
 ► Strongyloides stercoralis.
Faecal tests  ► Detection of C. difficile.
 ► Detection of enteric pathogens, including 
Salmonella, Shigella.
 ► Campylobacter, Escherichia coli O157 H7, 
Yersinia, Vancomycin-resistant enterococci, 
methicillin-resistant Staphylococcus 
aureus, Gram-negative mutidrug-resistant 
bacteria.
 ► Norovirus.
 ► Antigens and/or acid fast staining for 
Giardia sp and Cryptosporidium sp.
 ► Protozoa (including Blastocystis hominis) 
and helminths.
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randomisation process based on the results of this feasi-
bility study for potential stratifying factors in phase III.
blinding
The trial statistician, the assessing independent endos-
copist and the pathologist undertaking macroscopic and 
microscopic disease assessments will be blinded to the 
treatment allocation.
Participant timeline and schedule of assessment
Figure 1 and table 3 show the follow-up schedule and 
assessment for the trial. At baseline the study participants 
will undergo assessment for disease activity with validated 
tools (CUCQ-32, IBDex and Mayo Score) alongside a 
full history and physical examination. Baseline biopsies 
of the rectum for 16S rRNA analysis and immunological 
Figure 1 Study scheme flowchart.
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studies (IL-10 and IL-21), faecal samples for 16S rRNA 
analysis and metabolomic profile, blood tests (renal func-
tion, liver function, full blood count, C-reactive protein, 
metabolomic profile) will be obtained. Furthermore, 16S 
rRNA analysis for the donors’ faecal samples is performed. 
Subsequently, this will be studied together with 16S rRNA 
analysis of the participant’s faecal samples for the study of 
durability of engraftment after FMT treatments during a 
12-week follow-up period.
Follow-up visits will take place at week 1, 4, 8 and 12 
for all the three study groups. Participants will undergo 
clinical examination, blood and faecal testing to include 
faecal microbiota profiling using the 16S rRNA analysis 
and metabolomic profile and complete disease activity 
scoring questionnaires (CUCQ-32 and IBDex) at baseline 
and thereafter at 1 week. At the final assessment (week 
12), all subjects will also undertake a repeat flexible 
sigmoidoscopy for macroscopic assessment and biopsies 
for degree of inflammation or confirmation of remission. 
Participants who relapse or fail to improve after FMT will 
be offered conventional medical therapy.
Study participants will be instructed to inform the 
treating physician of any infectious symptom or new 
medical condition that develops after receiving FMT and 
a patient registry will be maintained.
Withdrawal
Participants may be withdrawn from the study if
 ► They wish to terminate treatment and/or follow-up 
assessments.
 ► Clinical features worsen during FMT or the 12 week 
follow-up period.
 ► The participant is non-compliant with the study in a 
manner that is either harmful to their health or inter-
feres with the validity of the study results.
 ► Participants who withdraw their consent may not wish 
for their data to be used—if this is the case then it will 
be deleted.
data collection and management
Data collection will be performed at baseline, week 1, 4, 8 
and 12 as described in table 3. All data is to be recorded 
on the case report form (CRF)in an anonymised format 
against a unique participant number.
Data will be transferred to a computer database without 
patient identifiable data and analysed once all results 
have been collected. The trial database will have built in 
measures to assess data quality at time of input and stored 
securely.
Metabolic profiling
We will use both untargeted (1 hour NMR) and targeted 
quantitative approaches such as high-performance liquid 
chromatography-mass spectrometry to analyse a panel of 
gut microbial cometabolites involved in cell signalling, 
namely SCFAs, bile acids, indoles and cresols and branch 
Table 3 Follow-up schedule and assessments
Baseline Week 1 Week 4 Week 8 Week 12
Questionnaires
  CUCQ-32 • • • • •
  IBDex • • • • •
  Mayo score • •
Endoscopy assessment
  Sigmoidoscopy • •
  Rectal biopsy • •
Histology assessment
  Histological grading • •
  Mucosal 16S sequencing • •
  Mucosal IL-10 • •
  Mucosal IL-21 • •
Blood tests
  Renal profile • • • • •
  Liver profile • • • • •
  Full blood count • • • • •
  C-reactive protein • • • • •
  Metabolomic profile • • • • •
Faecal sample assessment
  16S sequencing • • • • •
  Metabolomic profile • • • • •
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chain amino acids. This will include a novel eicosanoid 
assay36 for precision measurement of pro and anti-in-
flammatory regulators and the use of a bile acid assay.37 
Metabolome data will be analysed by several multivar-
iate ordinations including principal component anal-
yses, non-metric multidimensional scaling Kruskal-Wallis 
independent tests, and multivariate analysis of variance 
with Bonferroni correction. We will create receiver oper-
ating curves for both multivariate models and individual 
metabolites for key clinical outcomes. Metabolic reaction 
networks of metabolites found differentially expressed 
between different transplants will be created using the 
MetaboNetworks software.38
Participant rights and confidentiality
The chief investigator will be the custodian of the data. 
Information with regards to study participants will be 
kept confidential and managed in accordance with the 
Data Protection Act, National Health Service Caldicott 
Guardian, The Research Governance Framework for 
Health and Social Care and Research Ethics Committee 
Approval.
There will be no patient identifiable data on the CRF 
and a unique participant number will be allocated. The 
principal investigator will hold the key to the coded 
number of the participants only. Only the principal 
investigator will have access to the patient identifiable 
information.
statistical analysis
Both descriptive and exploratory data analysis will be 
performed. For each group, we will calculate the number 
of participants approached and/or assessed for eligibility, 
randomised and received the treatment. Thus, we will 
calculate the recruitment and retention rate along with 
the rate of adverse events. Descriptive statistics (mean, 
SD, 95% CI) for continuous outcomes (eg, CUCQ-32 
Score, Mayo score) and raw count (n, %) for categorical 
outcomes (eg, renal profile, liver profile, histological 
grading) will be reported as per the clinical endpoints.
All these summary statistics will be provided as per base-
line and other follow-ups (as appropriate to the outcome 
measure) and with respect to the three treatment arms. 
All the analysis and data preparation will be performed 
using SPSS v.22.0 as a validated statistical software for clin-
ical trials.
safety measures
An adverse event (AE) is defined as any untoward medical 
occurrence in a patient after administration of the study 
intervention (FMT) that does not necessarily have to have 
a causal relationship with this treatment. Serious adverse 
event (SAE) is any adverse experience occurring during 
or after FMT that results in either death, life-threat-
ening experience or requiring inpatient hospitalisation, 
persistent or significant disability or incapacity. SAEs will 
be notified to the study sponsor within 24 hours and to 
the Research Ethics Committee (REC) within 15 days. 
AEs that are expected for patients undergoing FMT, 
and symptoms expected from UC, are specified in the 
protocol and will not require to be reported as adverse 
events. FMT-related AEs are procedure-related symptoms 
such as bloating, transient fever or abdominal discomfort 
as reported by previously reported studies.
Quality assurance
The research and development quality assurance officer 
has performed a monitoring prioritisation assessment to 
assess the impact of trial participation on the rights and 
safety of participants and the reliability of trial results. 
This has guided the development of procedures in the 
trial with respect to informed consent, confidentiality and 
trial monitoring. Monitoring visits to the site will be made 
every 3 months during the study to ensure that all aspects 
of the protocol are followed. The quality assurance officer 
will also monitor the study after the first participant has 
been recruited. The monitoring visit timeframe can 
be changed depending on the monitoring findings. A 
quality assurance programme is also in place to ensure 
adherence to the study protocol. Major and minor devia-
tions will be collected.
Endosocopy: One of several JAG accredited gastroen-
terologists or colorectal surgeons from hospitals of the 
Abertawe Bro Morgannwg University's Health Board will 
perform the sigmoidoscopy assessment at baseline and 
week 12. The study team will ensure that the endosco-
pist performing the 12-week assessment is blinded to the 
intervention that the patient has received. Endoscopic 
photographs taken at baseline and at final assessment will 
be independently assessed by a blinded expert to provide 
quality assurance for this outcome measure.
Pathology: A standardised protocol based on RCPath 
guidelines will be used for histological assessment of the 
disease as per standard of care by consultant pathologists.
Patient and public involvement
Patients with UC were surveyed during the trial design 
stage to ascertain willingness to participate in the trial as 
described. All seven patients approached indicated by 
return of questionnaire their willingness to be recruited 
into the trial.
The investigators will invite IBD-specific charitable 
organisations and their patient representatives to help 
disseminate the findings of the feasibility trial and to 
design phase III.
Ethics and dissemination
The chief investigator will ensure that the trial is 
conducted in compliance with the principles of the 
Declaration of Helsinki (1996), and in accordance with 
all applicable regulatory requirements including but not 
limited to the Research Governance Framework, Trust 
and Research Office policies and procedures and any 
subsequent amendments. Written informed consent will 
be obtained from all participants. SAEs will be reported 
to the study sponsor and the regional ethics committee. 
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Trial results will be disseminated through oral presenta-
tions at national conferences and through peer-reviewed 
publication, which will include named members of the 
Trial Management Group (TMG) who meet the three 
criteria of scholarship (design, execution, analysis and/
or interpretation of the data), authorship (drafting, 
reviewing and revision of the manuscript) and approval 
(approving the manuscript to be published). Participants 
in the study will be given a copy of the results and a final 
report will be written by the TMG for the funding body 
and the REC. Results will be used to aid in the develop-
ment of a definitive phase III trial.
dIsCussIon
A recently published systematic review on the usage of 
FMT in IBD concluded that overall 36% of patients with 
UC achieved clinical remission (a total of 41 studies and 
four randomised controlled trials (RCTs)).39 Meta-anal-
ysis, which included 4 RCTs (a total of 140 individuals), 
demonstrated that FMT was significantly linked to clinical 
remission with a pooled OR of 2.89, 95% CI of 1.36 to 6.13 
and p-value of 0.016.
The number of FMT studies with high methodological 
quality has increased of late, yet the optimal conditions 
for durable FMT engraftment and maximal remission are 
presently unclear for UC. Table 4 summarises the current 
knowledge gaps in the application of FMT in UC.
Current studies are difficult to interpret as there is no 
universally agreed definition of remission as an endpoint 
in UC clinical trials to date.40 Furthermore, a lack of 
homogeneity of clinical trial protocols makes comparison 
of such studies more difficult to comprehend and these 
clinical trials are no exception. Moreover, different clin-
ical trials use different patient groups, donors, treatment 
dose, routes, frequency and pretreatment medications. 
These multiple variables make the comparison of studies 
very challenging, although all studies appear to demon-
strate promising results for the usage of FMT in active 
UC. Finally, and most importantly, patients recruited 
in published RCTs had been on previous conventional 
medical therapy until given the FMT treatment if not 
being assigned to further medical treatment. This 
makes the interpretation of the magnitude of treatment 
response to FMT very difficult.
Although the efficacy of FMT in UC appears to be 
promising, more clarity is required around optimal treat-
ment conditions through a rigorous study. This study 
will estimate the efficacy of rectally administered FMT in 
treatment naïve patients towards the design of a definitive 
trial. This phase II study allows us not only to estimate 
the magnitude of treatment response to FMT in UC, but 
also to determine the changes and durability of engraft-
ment of the gut microbiota after FMT treatment. Further-
more, we will study the dose response by comparing one 
dose only and five daily doses towards establishing the 
optimum dosage of rectally administered FMT treatment 
for UC. There is a fundamental lack of mechanistic data 
to support the use of FMT in clinical practice. Bacteria 
represent a diverse and highly active chemical engine 
that creates a suite of biologically active small molecules 
through secondary metabolism. The critical function 
of these target metabolites in the initiation and mainte-
nance of systemic inflammation remains poorly defined 
and this trial will provide a detailed insight into the role 
Table 4 Uncertainties for the optimal application of faecal microbiota transplantation (FMT) in ulcerative colitis (UC)
Human gut microbiota  ► Responsible pathogens and their roles.
 ► Microbiome profiling techniques.
FMT preparations  ► Frozen versus fresh.
 ► Donor screening protocol.
 ► Preparation methodology.
Donors  ► Related versus unrelated.
 ► Single donor versus multiple donors.
Pre-medications/preparation  ► Bowel preparation.
 ► Antibiotics versus non-antibiotics.
FMT in clinical application  ► Dose.
 ► Administration routes.
 ► FMT alone versus with other traditional medications.
 ► Durability of engraftment.
 ► Who to treat—active, remission, refractory.
 ► Adverse effects.
 ► Long-term effects and safety.
 ► Long-term effects after transplant.
Clinical remission  ► How to assess clinical response.
 ► How to define clinical remission.
 ► When to stop FMT treatment.
 ► Maintenance dose required for remission.
 ► Postremission dietary modification.
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of the gut microbiome in UC therapy that have the poten-
tial to stratify care in the future and improve the precision 
of this intervention.
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